Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival

Rhea-AI Summary

Outlook Therapeutics, a biopharmaceutical company, will present at the Telluride Retina Film Festival from February 3-5, 2022. The event will feature a corporate overview highlighting the company's efforts to develop ONS-5010, the first FDA-approved ophthalmic formulation of bevacizumab for retinal treatments, including wet AMD and DME. If approved, ONS-5010 will be marketed in the U.S., U.K., Europe, Japan, and other regions. Outlook Therapeutics aims to submit its BLA to the FDA under the PHSA 351(a) pathway.

News Market Reaction

-6.71%

1 alert

-6.71% News Effect

On the day this news was published, OTLK declined 6.71%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

ISELIN, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that members of management will be presenting at and sponsoring the Telluride Retina Film Festival taking place February 3-5, 2022 in Telluride, Colorado.

As part of the event, Outlook Therapeutics will present a corporate overview. To learn more about the event, please visit tellurideretinafilmfestival.org.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com

FAQ

What is Outlook Therapeutics presenting at the Telluride Retina Film Festival in 2022?

Outlook Therapeutics is presenting a corporate overview at the Telluride Retina Film Festival from February 3-5, 2022.

When is the Telluride Retina Film Festival taking place?

The Telluride Retina Film Festival will occur from February 3-5, 2022.

What is ONS-5010 developed by Outlook Therapeutics?

ONS-5010 is an investigational ophthalmic formulation of bevacizumab, aiming to be the first FDA-approved for retinal indications.

What conditions does ONS-5010 target?

ONS-5010 targets retinal diseases including wet AMD, DME, and BRVO.

What regulatory pathway will Outlook Therapeutics use for ONS-5010 submission?

Outlook Therapeutics plans to submit ONS-5010 to the U.S. FDA using the BLA under the PHSA 351(a) regulatory pathway.

Will ONS-5010 be available internationally?

If approved, ONS-5010 is expected to be available in the U.S., U.K., Europe, Japan, and other markets.